Organon announced today that the FDA has cleared the marketing of NDA019796, a decision that allows the company to expand its product portfolio and capitalize on an anticipated surge in demand following regulatory approval. This new authorization significantly strengthens Organon's commercial standing within the specialty pharmaceutical sector, positioning the firm to impact long-term revenue growth.